Malignant pleural mesothelioma: recent developments
K Sinn, B Mosleh, MA Hoda - Current opinion in oncology, 2021 - journals.lww.com
Malignant pleural mesothelioma: recent developments : Current Opinion in Oncology Malignant
pleural mesothelioma: recent developments : Current Opinion in Oncology Log in or Register …
pleural mesothelioma: recent developments : Current Opinion in Oncology Log in or Register …
[HTML][HTML] Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to
inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of …
inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of …
[HTML][HTML] British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I Woolhouse, L Bishop, L Darlison, D De Fonseka… - Thorax, 2018 - thorax.bmj.com
Refer all patients with a chest X-ray suggestive of MPM urgently (via the 2-week wait
suspected cancer pathway in England and Wales). Consider referral for further investigation …
suspected cancer pathway in England and Wales). Consider referral for further investigation …
[HTML][HTML] Consensus report of the 2015 Weinman international conference on mesothelioma
Abstract On November 9 and 10, 2015, the International Conference on Mesothelioma in
Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of …
Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of …
[HTML][HTML] Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee …
AS Tsao, OW Lindwasser, AA Adjei… - Journal of Thoracic …, 2018 - Elsevier
Abstract On March 28–29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy
Steering Committee, International Association for the Study of Lung Cancer, and …
Steering Committee, International Association for the Study of Lung Cancer, and …
HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients
A Napolitano, DJ Antoine, L Pellegrini, F Baumann… - Clinical Cancer …, 2016 - AACR
Purpose: To determine whether serum levels of high mobility group box protein 1 (HMGB1)
could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and …
could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and …
Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer
M Rigon, L Mutti, M Campanella - Molecular Oncology, 2024 - Wiley Online Library
Mesothelioma is a type of late‐onset cancer that develops in cells covering the outer surface
of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining …
of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining …
Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?
E Pulford, K Huilgol, D Moffat, DW Henderson… - Disease …, 2017 - Wiley Online Library
Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes.
Early diagnosis and accurate prognostication remain problematic. BAP1 is a tumour …
Early diagnosis and accurate prognostication remain problematic. BAP1 is a tumour …
[HTML][HTML] Diagnosis and prognosis—review of biomarkers for mesothelioma
HH Sun, A Vaynblat, HI Pass - Annals of Translational Medicine, 2017 - ncbi.nlm.nih.gov
Malignant pleural mesothelioma (MPM) is an aggressive disease arising in pleural cell
lining and is associated with asbestos exposure. Today, there is a rising incidence of MPM …
lining and is associated with asbestos exposure. Today, there is a rising incidence of MPM …
[HTML][HTML] High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
MA Hoda, A Rozsas, E Lang, T Klikovits, Z Lohinai… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Abstract Activin A (ActA)/follistatin (FST) signaling has been shown to be deregulated in
different tumor types including lung adenocarcinoma (LADC). Here, we report that serum …
different tumor types including lung adenocarcinoma (LADC). Here, we report that serum …